litlas
ログインアカウント作成

Norikazu Masuda

1999–2025 年に発表

105
論文数
24,650
被引用数
56
h 指数
101
i10 指数

被引用数

Norikazu Masuda の年別被引用数1964 年: 被引用 2 件1982 年: 被引用 1 件1993 年: 被引用 2 件1996 年: 被引用 1 件2000 年: 被引用 1 件2001 年: 被引用 5 件2002 年: 被引用 11 件2003 年: 被引用 5 件2004 年: 被引用 8 件2005 年: 被引用 3 件2006 年: 被引用 9 件2007 年: 被引用 13 件2008 年: 被引用 14 件2009 年: 被引用 8 件2010 年: 被引用 18 件2011 年: 被引用 29 件2012 年: 被引用 14 件2013 年: 被引用 20 件2014 年: 被引用 19 件2015 年: 被引用 31 件2016 年: 被引用 83 件2017 年: 被引用 122 件2018 年: 被引用 257 件2019 年: 被引用 935 件2020 年: 被引用 1,283 件2021 年: 被引用 1,433 件2022 年: 被引用 1,241 件2023 年: 被引用 1,103 件2024 年: 被引用 1,510 件2025 年: 被引用 743 件2026 年: 被引用 29 件1965〜1981 年は被引用が無いため表示していません1983〜1992 年は被引用が無いため表示していません1994〜1995 年は被引用が無いため表示していません1997〜1999 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,581 件、この内訳の 22.5%中国: 引用元論文 1,186 件、この内訳の 10.3%イタリア: 引用元論文 792 件、この内訳の 6.9%イギリス: 引用元論文 599 件、この内訳の 5.2%ドイツ: 引用元論文 541 件、この内訳の 4.7%フランス: 引用元論文 538 件、この内訳の 4.7%スペイン: 引用元論文 525 件、この内訳の 4.6%日本: 引用元論文 501 件、この内訳の 4.4%カナダ: 引用元論文 393 件、この内訳の 3.4%オーストラリア: 引用元論文 323 件、この内訳の 2.8%韓国: 引用元論文 298 件、この内訳の 2.6%ベルギー: 引用元論文 281 件、この内訳の 2.5%
0%22.5%その他 25.4%

機関

分野

  • Medicine65%
  • Biochemistry, Genetics and Molecular Biology30.1%
  • Immunology and Microbiology1.7%
  • Engineering0.6%
  • Computer Science0.6%
  • Materials Science0.4%
  • その他1.6%

トピック

  • Advanced Breast Cancer Therapies10.5%
  • Breast Cancer Treatment Studies7.5%
  • HER2/EGFR in Cancer Research7.2%
  • Cancer Immunotherapy and Biomarkers5%
  • PARP inhibition in cancer therapy4.3%
  • Cancer-related Molecular Pathways3.8%
  • その他61.7%

共著者

全論文

検索で開く
  1. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

    著者: Javier Cortés, Hope S. Rugo, David W. Cescon, Seock‐Ah Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H. Barrios, José Manuel Pérez-García, Hiroji Iwata, Norikazu Masuda, Marco Torregroza Otero, Erhan Gokmen, Sherene Loi, Zifang Guo, Xuan Zhou, Vassiliki Karantza, Wilbur Pan, Peter Schmid - New England Journal of Medicine 2022 被引用: 1,096

  2. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

    著者: Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Suzette Delaloge, Wěi Li, Nadine Tung, Anne Armstrong, Wenting Wu, Carsten Goessl, Sarah Runswick, PierFranco Conte - New England Journal of Medicine 2017 被引用: 3,214

  3. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

    著者: Javier Cortés, David W. Cescon, Hope S. Rugo, Zbigniew Nowecki, Seock‐Ah Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H. Barrios, Esther Holgado, Hiroji Iwata, Norikazu Masuda, Marco Torregroza Otero, Erhan Gökmen, Sherene Loi, Zifang Guo, Jing Zhao, Gursel Aktan, Vassiliki Karantza, Peter Schmid, F. Vidal Luis, Gomez Abuin Gonzalo, Diego Kaen, Kowalwszyn Ruben, Molina Matias, Varela Mirta, Sally Baron-Hay, Begbie Stephen, Clingan Philip, Loi Sherene, Sabanathan Dhanusha, Andrea Gombos, Donatienne Taylor, Carlos Barrios, Leandro Brust, Costa Fabiano, de Freitas Junior Ruffo, Roberto Hegg, Lacerda Domicio Carvalho, Lissa Fernando Cezar Toniazzi, Rocha Roberto Odebrecht, Scalabrini Neto Antonio Orlando, Silva Felipe, Cescon David, Danielle Charpentier, Ferrario Cristiano, Xinni Song, Yu Joanne, Alejandro Acevedo, Gallardo Carlos, Salas Claudio, Sanchez Cesar, Eduardo Yañez, Gomez Diaz Alvaro, Sanchez Jesus, Holeckova Petra, Kral Zdenek, Bohuslav Melichar, Katarína Petráková, Prausova Jana, Vesna Glavicic, Jakobsen Erik, Jensen Jeanette, Søren Linnet, Tamás Lörincz, Bonnefoi Herve, Isabelle Desmoulins, Goncalves Anthony, Hardy-Bessard Anne-Claire, Luís Teixeira, Blohmer Jens-Uwe, Fasching Peter, Dirk Forstmeyer, Nadia Harbeck, Huober Jens, Kaczerowsky Flores de Sousa Anna, Kurbacher Christian, Sibylle Loibl, Lueftner Diana, Park-Simon Tjoung-Won, Schumann Raquel Von, Pauline Wimberger, Chow Louis, Kwong Ava, Ngan Kai Cheong Roger, Peter Arkosy, Tibor Csőszi, Zsuzsanna Kahán, Landherr László, Mahr Karoly, Gábor Rubovszky, Crown John, Kelly Catherine, O'Reilly Seamus, Saverio Cinieri, DAlessio Antonietta, Ricevuto Enrico, Tomoyuki Aruga, Takaaki Fujii, Inoue Kenichi ほか 127 名 - The Lancet 2020 被引用: 1,800

  4. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

    著者: Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, Young‐Hyuck Im, Eun Sook Lee, Isao Yokota, Katsumasa Kuroi, Seock‐Ah Im, Byeong‐Woo Park, Sung‐Bae Kim, Yasuhiro Yanagita, Shinji Ohno, Shintaro Takao, Kenjiro Aogi, Hiroji Iwata, Joon Jeong, Aeree Kim, Kyong Hwa Park, Hironobu Sasano, Yasuo Ohashi, Masakazu Toi - New England Journal of Medicine 2017 被引用: 1,887

  5. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

    著者: George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva‐Maria Grischke, Martin Frenzel, Yong Lin, Susana Barriga, Ian C. P. Smith, Nawel Bourayou, Antonio Llombart‐Cussac - Journal of Clinical Oncology 2017 被引用: 1,656

  6. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    著者: Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko, Jungsil Ro, Seock‐Ah Im, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Ke Zhang, Kathy Puyana Theall, Yuqiu Jiang, Cynthia Huang Bartlett, María Koehler, Dennis J. Slamon - The Lancet Oncology 2016 被引用: 1,822

  7. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

    著者: Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro, Igor Bondarenko, Seock‐Ah Im, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Sibylle Loibl, Fabrice André, Kathy Puyana Theall, Xin Huang, C. Giorgetti, Cynthia Huang Bartlett, Massimo Cristofanilli - New England Journal of Medicine 2018 被引用: 1,293

  8. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

    著者: George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva‐Maria Grischke, PierFranco Conte, Yi Lu, Susana Barriga, Karla Hurt, Martin Frenzel, Stephen Johnston, Antonio Llombart‐Cussac - JAMA Oncology 2019 被引用: 987

  9. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

    著者: Mark E. Robson, Nadine Tung, PierFranco Conte, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Norikazu Masuda, Suzette Delaloge, W. Li, Anne Armstrong, Weiwen Wu, Carsten Goessl, Sarah Runswick, Susan M. Domchek - Annals of Oncology 2019 被引用: 760

  10. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

    著者: Cristina Saura, Mafalda Oliveira, Yin‐Hsun Feng, Ming‐Shen Dai, Shang-Wen Chen, Sara A. Hurvitz, Sung‐Bae Kim, Beverly Moy, Suzette Delaloge, William J. Gradishar, Norikazu Masuda, Markéta Palácová, Maureen Trudeau, Johanna Mattson, Yoon Sim Yap, Ming‐Feng Hou, Michelino De Laurentiis, Yu‐Min Yeh, Hong‐Tai Chang, Thomas Yau, Hans Wildiers, Barbara Haley, Daniele Fagnani, Yen‐Shen Lu, John Crown, Johnson Lin, Masato Takahashi, Toshimi Takano, Miki Yamaguchi, Takaaki Fujii, Bin Yao, Judith D. Bebchuk, Kiana Keyvanjah, Richard Bryce, Adam Brufsky, for the NALA Investigators - Journal of Clinical Oncology 2020 被引用: 609

  11. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

    著者: Massimo Cristofanilli, Hope S. Rugo, Seock‐Ah Im, Dennis J. Slamon, Nadia Harbeck, Igor Bondarenko, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Hiroji Iwata, Ben O’Leary, Fabrice André, Sibylle Loibl, Eustratios Bananis, Yuan Liu, Xin Huang, Sindy Kim, Maria Jose Lechuga Frean, Nicholas C. Turner - Clinical Cancer Research 2022 被引用: 198

  12. Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial

    著者: Ian E. Krop, Norikazu Masuda, Toru Mukohara, Shunji Takahashi, Takahiro Nakayama, Kenichi Inoue, Hiroji Iwata, Yutaka Yamamoto, Ricardo H. Álvarez, Tatsuya Toyama, Masato Takahashi, Akihiko Osaki, Shigehira Saji, Yasuaki Sagara, Joyce O’Shaughnessy, Shoichi Ohwada, Kumiko Koyama, Tatsuya Inoue, Li Li, Parul Patel, Joseph Mostillo, Yoshimi Tanaka, David Sternberg, Dalila Sellami, Kan Yonemori - Journal of Clinical Oncology 2023 被引用: 122

  13. Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria

    著者: Hiroshi Katayama, Yukinori Kurokawa, Kenichi Nakamura, Hiroyuki Ito, Yukihide Kanemitsu, Norikazu Masuda, Yasuhiro Tsubosa, Toyomi Satoh, Akira Yokomizo, Haruhiko Fukuda, Mitsuru Sasako - Surgery Today 2015 被引用: 782

  14. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: José Baselga, Seock‐Ah Im, Hiroji Iwata, Javier Cortés, Michele De Laurentiis, Zefei Jiang, Carlos L. Arteaga, W. Jonat, Mark Clemons, Yoshinori Ito, Ahmad Awada, Stephen Chia, Agnieszka Jagiełło-Gruszfeld, Barbara Pistilli, Ling‐Ming Tseng, Sara A. Hurvitz, Norikazu Masuda, Masato Takahashi, Peter Vuylsteke, Soulef Hachemi, Bharani Dharan, Emmanuelle di Tomaso, Patrick Urban, Cristian Massacesi, Mario Campone - The Lancet Oncology 2017 被引用: 539

  15. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gϋnter von Minckwitz, Stephen Chia, Janine Mansi, Carlos H. Barrios, Michael Gnant, Z. Tomasevic, Neelima Denduluri, Robert Šeparović, Erhan Gökmen, Anna Bashford, Manuel Ruíz Borrego, Sung‐Bae Kim, Erik Jakobsen, A. Ciceniene, Kenichi Inoue, Friedrich Overkamp, Joan B. Heijns, Anne Armstrong, John S. Link, Anil A. Joy, Richard Bryce, Alvin Wong, Susan Moran, Bin Yao, Feng Xu, Alan Auerbach, Marc Buyse, Arlene Chan, Vernon Harvey, Rudolf Tomek, Nicholas J. Robert, Ira Gore, John W. Smith, Norikazu Masuda, S. Di Sean Kendall, William Graydon Harker, Katarína Petráková, Ángel Guerrero‐Zotano, Amparo Ruiz Simón, Zora Neskovic Konstantinovic, Nicholas Iannotti, Pierfrancesco Tassone, Gladys Rodriguez, Noelia Jáñez Martínez, Carmen Crespo Massieu, Snezana Smickoska, Işıl Somali, Uğur Yılmaz, Mirta Garcia Alonso, Adolfo Rosales, Soeren Cold, Ann Knoop, Debra A. Patt, Beth A. Hellerstedt, Serafin Morales Murillo, Ingrid A. Mayer, Julie A. Means‐Powell, Rina Hui, Francis M. Senecal, Richard Hendry De Boer, Zhenzhou Shen, A.A. Luczak, Joanna W.Y. Chui, Janice Tsang, István Láng, Yoshiaki Rai, Yasuo Hozumi, Albert J. ten Tije, Manish Bhandari, Cynthia R. Osborne, Shoichiro Ohtani, Kenji Higaki, Kenichi Watanabe, Kazunori TAGUCHI, Masato Takahashi, Sladjana Filipovic, Vincent Hansen, Vijayarama Phooshkooru Rao, Manish Gupta, Petar Petrov, Bruno Coudert, Željko Vojnović, Zsofia Polya, Toshiko Miyaki, Naohito Yamamoto, Stephen Brincat, Krzysztof Leśniewski-Kmak, Ewa Chmielowska, Ruemu Birhiray, Marc L. Citron, Steven W. Papish, William L. Berry, Sven Tyge Langkjer, José Á. García-Sáenz ほか 526 名 - The Lancet Oncology 2017 被引用: 589

  16. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

    著者: Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Suzette Delaloge, Nadine Tung, Anne Armstrong, Mike Dymond, Anitra Fielding, A. Allen, PierFranco Conte - European Journal of Cancer 2023 被引用: 111

  17. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3

    著者: Hope S. Rugo, Jens Huober, José Á. García-Sáenz, Norikazu Masuda, Joohyuk Sohn, Valérie André, Susana Barriga, Joanne Cox, Matthew P. Goetz - The Oncologist 2020 被引用: 172

  18. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    著者: Arlene Chan, Suzette Delaloge, Frankie A. Holmes, Beverly Moy, Hiroji Iwata, Vernon Harvey, Nicholas J. Robert, Tajana Silovski, Erhan Gökmen, Gϋnter von Minckwitz, Bent Ejlertsen, Stephen Chia, Janine Mansi, Carlos H. Barrios, Michael Gnant, Marc Buyse, Ira Gore, John W. Smith, Graydon Harker, Norikazu Masuda, Katarína Petráková, Ángel Guerrero Zotano, Nicholas Iannotti, Gladys Rodriguez, Pierfrancesco Tassone, Alvin Wong, Richard Bryce, Yining Ye, Bin Yao, Miguel Martín - The Lancet Oncology 2016 被引用: 565

  19. Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)

    著者: Jun Masuda, Hitomi Sakai, Junji Tsurutani, Yuko Tanabe, Norikazu Masuda, Tsutomu Iwasa, Masato Takahashi, Manabu Futamura, Koji Matsumoto, Kenjiro Aogi, Hiroji Iwata, Mari Hosonaga, Toru Mukohara, Kiyoshi Yoshimura, Chiyo K. Imamura, Sakiko Miura, Toshiko Yamochi, Hidetaka Kawabata, Hiroyuki Yasojima, Nobumoto Tomioka, Kenichi Yoshimura, Toshimi Takano - Journal for ImmunoTherapy of Cancer 2023 被引用: 66

  20. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

    著者: Fabrice André, Ruth O’Regan, Mustafa Özgüroğlu, Masakazu Toi, Binghe Xu, Guy Jérusalem, Norikazu Masuda, Sharon Wilks, Francis P. Arena, Claudine Isaacs, Yoon Sim Yap, Zsuzsanna Pápai, István Láng, Anne Armstrong, Guillermo Lerzo, Michelle White, Kunwei Shen, Jennifer K. Litton, David Chen, Yufen Zhang, Shyanne Ali, Tetiana Taran, Luca Gianni - The Lancet Oncology 2014 被引用: 491

  21. Abstract GS01-10: HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer

    著者: Sara A. Hurvitz, Sherene Loi, Joyce O’Shaughnessy, Alicia Okines, Sara M. Tolaney, Joohyuk Sohn, Cristina Saura, Xiaofu Zhu, David Cameron, Thomas Bachelot, Erika Hamilton, Giuseppe Curigliano, Antonio C. Wolff, Nadia Harbeck, Norikazu Masuda, Linda T. Vahdat, Khalil Zaman, Frances Valdes-Albini, Margaret Block, Timothy Pluard, Tira J. Tan, Chelsea Gawryletz, Arlene Chan, Philippe L. Bédard, Rinat Yerushalmi, Binghe Xu, Konstantinos Tryfonidis, Michael Schmitt, Joan Xie, Virginia F. Borges - Cancer Research 2024 被引用: 34

  22. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis

    著者: Naoki Niikura, Naoki Hayashi, Norikazu Masuda, Seiki Takashima, Rikiya Nakamura, Kenichi Watanabe, Chizuko Kanbayashi, M. Ishida, Yasuo Hozumi, Michiko Tsuneizumi, Naoto Kondo, Yoichi Naito, Yayoi Honda, Akira Matsui, Tomomi Fujisawa, Risa Oshitanai, Hiroyuki Yasojima, Yutaka Tokuda, Shigehira Saji, Hiroji Iwata - Breast Cancer Research and Treatment 2014 被引用: 199

  23. Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).

    著者: Ian E. Krop, Norikazu Masuda, Toru Mukohara, Shunji Takahashi, Takahiro Nakayama, Kenichi Inoue, Hiroji Iwata, Tatsuya Toyama, Yutaka Yamamoto, Damien Mikael Hansra, Masato Takahashi, Akihiko Osaki, Kumiko Koyama, Tatsuya Inoue, Takatoshi Yonekura, Joseph Mostillo, Shoichi Ohwada, Yoshimi Tanaka, David Sternberg, Kan Yonemori - Journal of Clinical Oncology 2022 被引用: 66

  24. Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)

    著者: Yukinori Ozaki, Junji Tsurutani, Toru Mukohara, Tsutomu Iwasa, Masato Takahashi, Yuko Tanabe, Hidetaka Kawabata, Norikazu Masuda, Manabu Futamura, Hironobu Minami, Koji Matsumoto, Kenichi Yoshimura, Shigehisa Kitano, Toshimi Takano - European Journal of Cancer 2022 被引用: 36